/

Empresas

Ap

No verificado

Aptar Pharma

Sobre qué escribimos

BiotecnologíaFarmacéuticaIndustriaSaludSanidad

10 Comunicados de prensa

Ver todos los comunicados de prensa

25/09/2025

Industria

Ciencia

Material médico sanitario

Medicina - Varios

Sanidad

Biotecnología

Farmacéutica

Salud

Aptar Pharma Continues Global Expansion with Opening of New R&D Center in France

Fuente

Editor

1.00

0

18/09/2025

Aptar Pharma’s Unidose System Delivers Enbumyst™, First U.S. FDA-Approved Intranasal Diuretic

Fuente

Editor

1.00

0

05/09/2025

Aptar Pharma and Dianosic Announce Exclusive Partnership to Advance the Active Resorbable Intranasal Scaffold Platform for the Treatment of Chronic Allergic Rhinitis and Chronic Rhinosinusitis

Fuente

Editor

1.00

0

29/07/2025

Aptar’s First Nasal Pump Made with 52% Bio-based Material* now Available with Haleon’s Otrivin® Brand

Fuente

Editor

1.00

0

15/07/2025

Ciencia

Tecnología de la construcción

Mercado inmobiliario

Medicina - Varios

Biotecnología

Sanidad

Salud

Farmacéutica

Mercado de valores

Industria

Aptar Pharma Bolsters Clinical Trial Capabilities with Strategic Materials Manufacturing Acquisition

Fuente

Editor

1.00

0

27/02/2025

RDD Europe 2025, Co-Organized by Aptar Pharma and RDD Online, Celebrates 20 Years

Fuente

Editor

1.00

0

07/11/2024

Aptar Pharma Enters into Exclusive Agreement with Cambridge Healthcare Innovations to Commercialize the Quattrii Dry Powder Inhaler Platform

Fuente

Editor

1.00

0

09/10/2024

Aptar Pharma Acquires Device Technology Assets of SipNose to Further Expand Intranasal Drug Delivery Portfolio

Fuente

Editor

1.00

0

24/09/2024

Aptar Pharma Celebrates North America Capacity Expansion

Fuente

Editor

1.00

0

09/09/2024

Multimedia

Mercado laboral

Industria

Material médico sanitario

Biotecnología

Sanidad

Salud

Farmacéutica

Aptar Pharma Enters into Exclusive Agreement with Pulmotree to Develop and Promote Kolibri™ Non-Propellant Liquid Inhaler Platform

Fuente

Editor

1.00

0

Seguidores

0

Compatibilidad

0